z-logo
open-access-imgOpen Access
Lnc RNA NR 2F1‐ AS 1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC 1 via miR‐363
Author(s) -
Huang Hai,
Chen Jie,
Ding ChengMing,
Jin Xin,
Jia ZeMing,
Peng Jian
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13605
Subject(s) - gene knockdown , oxaliplatin , rna , in vivo , microbiology and biotechnology , microrna , hepatocellular carcinoma , in vitro , cancer research , messenger rna , chemistry , competing endogenous rna , long non coding rna , biology , gene , cancer , biochemistry , colorectal cancer , genetics
Emerging evidence has validated the vital role of long non‐coding RNA (lnc RNA ) in the chemoresistance of cancer treatment. In the present study, we investigate the function of lnc RNA NR 2F1‐ AS 1 on oxaliplatin ( OXA ) resistance of hepatocellular carcinoma ( HCC ) and discover the underlying molecular mechanism. Results revealed that lnc RNA NR 2F1‐ AS 1 was up‐regulated in oxaliplatin‐resistant HCC tissue and cells using microarray analysis and RT ‐ PCR . Meanwhile, ABCC 1 protein was overexpressed in OXA ‐resistant HCC cells (Huh7/ OXA and HepG2/ OXA ). In vitro, NR 2F1‐ AS 1 knockdown reduced the invasion, migration, drug‐resistant gene ( MDR 1, MRP 5, LRP 1) and IC 50 value in Huh7/ OXA and HepG2/ OXA cells. In vivo, NR 2F1‐ AS 1 knockdown decreased the tumour weight of HCC cells. Bioinformatics tools and luciferase reporter assay confirmed miR‐363 targeted the 3′‐ UTR of NR 2F1‐ AS 1 and ABCC 1 mRNA , presenting that NR 2F1‐ AS 1 promoted ABCC 1 expression through endogenous sponging miR‐363. In summary, results conclude that NR 2F1‐ AS 1 regulates HCC OXA resistance through targeting miR‐363‐ ABCC 1 pathway, providing a vital theoretic mechanism and therapeutic target for HCC chemoresistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here